+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Seelos Therapeutics, Inc. (SEEL) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 43 Pages
  • August 2023
  • GlobalData
  • ID: 4315243
Seelos Therapeutics, Inc. (SEEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Seelos Therapeutics, Inc. (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-007, SLS-008, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.

Seelos Therapeutics, Inc. Key Recent Developments

  • May 15, 2023: Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
  • Nov 23, 2022: Seelos Therapeutics to hold a research and development update conference call and webcast on december 15, 2022
  • Mar 07, 2022: Seelos Therapeutics announces year-end 2021 business and clinical update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Seelos Therapeutics, Inc. - Key Facts
  • Seelos Therapeutics, Inc. - Key Employees
  • Seelos Therapeutics, Inc. - Key Employee Biographies
  • Seelos Therapeutics, Inc. - Major Products and Services
  • Seelos Therapeutics, Inc. - History
  • Seelos Therapeutics, Inc. - Company Statement
  • Seelos Therapeutics, Inc. - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Seelos Therapeutics, Inc. - Business Description
  • Seelos Therapeutics, Inc. - Corporate Strategy
  • Seelos Therapeutics, Inc. - SWOT Analysis
  • SWOT Analysis - Overview
  • Seelos Therapeutics, Inc. - Strengths
  • Seelos Therapeutics, Inc. - Weaknesses
  • Seelos Therapeutics, Inc. - Opportunities
  • Seelos Therapeutics, Inc. - Threats
  • Seelos Therapeutics, Inc. - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Seelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Seelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Seelos Therapeutics, Inc., Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 15, 2023: Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
  • Nov 23, 2022: Seelos Therapeutics to hold a research and development update conference call and webcast on december 15, 2022
  • Mar 07, 2022: Seelos Therapeutics announces year-end 2021 business and clinical update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Seelos Therapeutics, Inc., Key Facts
  • Seelos Therapeutics, Inc., Key Employees
  • Seelos Therapeutics, Inc., Key Employee Biographies
  • Seelos Therapeutics, Inc., Major Products and Services
  • Seelos Therapeutics, Inc., History
  • Seelos Therapeutics, Inc., Subsidiaries
  • Seelos Therapeutics, Inc., Key Competitors
  • Seelos Therapeutics, Inc., Ratios based on current share price
  • Seelos Therapeutics, Inc., Annual Ratios
  • Seelos Therapeutics, Inc., Interim Ratios
  • Seelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Seelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Seelos Therapeutics, Inc., Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Seelos Therapeutics, Inc., Performance Chart (2018 - 2022)
  • Seelos Therapeutics, Inc., Ratio Charts
  • Seelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Seelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acadia Pharmaceuticals Inc
  • Bayer Plc
  • Eli Lilly and Co
  • Intas Pharmaceuticals Ltd
  • Pfizer Inc
  • Sage Therapeutics Inc
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd